评论 来源:天天在线 时间:2023-05-26 12:51:32
(资料图)
5月26日,诺诚健华携公司自主研发的新型酪氨酸激酶2(Tyrosine Kinase 2,TYK2)抑制剂ICP-332首次亮相2023中关村论坛,并参与国际技术交易大会“新技术新产品首发与推介大会”。ICP-332是诺诚健华具有全球自主知识产权的1类创新药,属于新型口服TYK2抑制剂。目前中国尚无TYK2抑制剂类药物获批上市。I
标签:
上一篇:储能招标丨德阳市智能光储充放充电网络储能设备采购项目
下一篇:最后一页
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
22-09-30
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
22-04-11
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26
23-05-26